Article Text

Download PDFPDF

Original research article
Effect of ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials
  1. Ik Hur Teoh1 and
  2. Moulinath Banerjee1,2
  1. 1Department of Diabetes and Endocrinology, Royal Bolton Hospital, Bolton, UK
  2. 2Endocrine Sciences Research Group, Manchester University, Manchester, UK
  1. Correspondence to Dr Ik Hur Teoh; ikhur.teoh{at}


Background Ranolazine is an antianginal drug reported to have hypoglycaemic effects.

Objectives To assess the effect of ranolazine versus placebo on glycaemic control for adults with and without diabetes.

Methods A systematic search of seven databases was conducted to identify all randomised controlled trials that compared the effect of ranolazine versus placebo on haemoglobin A1c (HbA1c) and/or fasting plasma glucose (FPG) and/or incidence of hypoglycaemia. We used mean differences in HbA1c and FPG to express intervention effect estimates and analysed the data with random-effects model for meta-analyses using Revman 5.3.

Results We identified seven trials including 6543 subjects to assess the effect of ranolazine on HbA1c and/or FPG. A separate trial that included 944 subjects was included to assess the effect of ranolazine on hypoglycaemia. The change in HbA1c for all patients was −0.36% (95% CI −0.57% to −0.15%; p=0.0004, I2=78%). In patients with diabetes, the change in HbA1c was −0.41% (95% CI −0.58% to −0.25%; p<0.00001, I2=65%). There was no significant difference in FPG between ranolazine and placebo groups (−2.58 mmol/L, 95% CI −7.02 to 1.85; p=0.25; I2=49%) or incidence of hypoglycaemia between ranolazine and placebo groups (OR 1.70, 95% CI 0.89 to 3.26; p=0.61, I2=0%).

Conclusions Our meta-analytic findings support the fact that ranolazine improves HbA1c without increasing the risk of hypoglycaemia. It therefore has a potential of having an additional benefit of improving glycaemic control in patients with chronic stable angina and diabetes.

  • coronary artery disease
  • stable angina
  • macrovascular disease

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

View Full Text

Statistics from


  • Contributors MB has provided the conception and design of this meta-analysis. IHT carried out the literature search, data extracting and statistical analysis under MB guidance. All IHT work has later been independently checked by MB. IHT drafted the manuscript, whereas MB revised the manuscript critically for important intellectual content.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Data sharing statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.